TNF-α-Induced VEGF and MMP-9 Expression Promotes Hemorrhagic Transformation in Pituitary Adenomas by Xiao, Zhengzheng et al.
Int. J. Mol. Sci. 2011, 12, 4165-4179; doi:10.3390/ijms12064165 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
TNF-α-Induced VEGF and MMP-9 Expression Promotes 
Hemorrhagic Transformation in Pituitary Adenomas 
Zhengzheng Xiao 
1, Qin Liu 
2, Feng Mao 
1, Jun Wu 
1 and Ting Lei 
1,* 
1  Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of 
Science and Technology, Wuhan 430030, China; E-Mails: xzzxzz@yahoo.cn (Z.Z.X.); 
maofeng.tongji@yahoo.cn (F.M.); zma@nccu.edu (J.W.) 
2  Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of 
Science and Technology, Wuhan 430030, China; E-Mail: qliuunion@yahoo.cn 
*  Author to whom correspondence should be addressed; E-Mail: tlei.tongji@gmail.com;  
Tel.: +86-027-8366-8989; Fax: +86-027-8366-2594. 
Received: 6 June 2011; in revised form: 13 June 2011 / Accepted: 15 June 2011 /  
Published: 23 June 2011 
 
Abstract: Pituitary apoplexy is a clinical syndrome with unknown pathogenesis. Therefore, 
identifying the underlying mechanisms is of high clinical relevance. Tumor necrosis factor 
alpha (TNF-α) is a critical cytokine mediating various hemorrhagic events, but little is 
known about its involvement in pituitary apoplexy. Here we show that TNF-α may be an 
important regulator of hemorrhagic transformation in pituitary adenomas. In this study, 
sixty surgical specimens of hemorrhagic and non-hemorrhagic human pituitary adenomas 
were  examined.  Hemorrhagic  pituitary  adenomas  displayed  higher  protein  and  mRNA 
levels of TNF-α, vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 
(MMP-9) compared with those of non-hemorrhagic tumors. Exposure of MMQ pituitary 
adenoma cells to TNF-α induced VEGF and MMP-9 expression in vitro. Additionally, 
TNF-α  administration  caused  hemorrhagic  transformation  and  enhanced  VEGF  and  
MMP-9 expression in MMQ pituitary adenoma cell xenografts in mice. Blockers of VEGF 
or MMP-9, either alone or in combination, attenuated but not abrogated TNF-α mediated 
hemorrhagic transformation in xenografts. This study suggests that TNF-α may play a role 
in the development of intratumoral hemorrhage in pituitary adenomas via up-regulation of 
VEGF and MMP-9. 
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1. Introduction 
Pituitary  apoplexy  is  a  potentially  life-threatening  syndrome  resulting  from  hemorrhage, 
hemorrhagic infarction or infarction of a pre-existing pituitary adenoma [1]. The reported incidence  
of  apoplectic  pituitary  tumors  varies  from  0.6  to  10%  of  all  surgically  resected  adenomas  [2]. 
Pathological studies show that more than 60% of apoplectic pituitary adenomas display hemorrhage or 
hemorrhagic  infarction  [3].  However,  the  mechanisms  underlying  hemorrhagic  transformation  in 
pituitary adenomas remain unclear. Increasing evidence from recent studies suggests that TNF-α plays 
a  critical  role  in  the  development  of  various  hemorrhagic  events  [4–6].  TNF-α  is  a  well-known 
cytokine involved in multiple pathological processes such as angiogenesis,  destruction of vascular 
integrity,  and  vascular  hyperpermeability  [7],  which  promote  hemorrhagic  transformation  [6].  
The underlying mechanism has been proposed to be TNF-α mediated up-regulation of VEGF and  
MMP-9 [6,8–11]. 
VEGF,  a  growth  factor  which  has  essential  roles  in  vasculogenesis,  angiogenesis  and  vascular 
permeability [12], has been correlated with a propensity for hemorrhage in various tumors and vascular 
diseases. VEGF overexpression in U87 MG cells and U251 MG cells causes intratumoral hemorrhage 
in their xenografts [13,14]. VEGF administration aggravates hemorrhagic transformation in rats after 
transient focal  cerebral ischemia  [15]. The  involvement of VEGF in  the development of pituitary 
adenoma  hemorrhage  remains  controversial.  Arita  et  al.  [16]  found  a  positive  relation  between 
hemorrhage and VEGF protein expression in 39 human pituitary adenomas. However, other studies 
found no significant relation [17–19]. 
MMP-9 is known to degrade extracellular matrix around blood vessels leading to increased vascular 
permeability [20,21]. MMP-9 has been associated with hemorrhagic events in many clinical entities, 
such  as aneurysmal diseases [6], intraventricular  hemorrhage  in  premature infants [22],  metastatic 
brain tumors [8], anovulatory dysfunctional uterine bleeding [23], and arteriovenous malformations [9]. 
Moreover,  hemorrhagic  pituitary  adenomas  exhibit  higher  MMP-9  protein  expression  levels  than  
non-hemorrhagic tumors [24]. As suggested by previous findings, up-regulation of either VEGF or 
MMP-9 can cause instability of vessels [25], thereby predisposing to hemorrhagic events. 
Based on the fact that TNF-α and TNFR1 are present in normal and tumoral anterior pituitary  
cells [26,27], we hypothesized that TNF-α may enhance MMP-9 and VEGF expression, which, in turn, 
contributes to hemorrhagic transformation in pituitary adenomas via degrading components of vascular 
basement lamina and increasing vascular permeability. In the present study, the possible correlation 
between TNF-α and hemorrhage within pituitary adenomas was investigated. We evaluated TNF-α, 
VEGF and MMP-9 expression in surgical specimens of hemorrhagic and non-hemorrhagic pituitary 
adenomas.  Furthermore,  the  association  between  TNF-α  and  hemorrhagic  presentation  was  also 
identified in vitro and in vivo. Int. J. Mol. Sci. 2011, 12                       
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2. Results and Discussion 
2.1. Clinical Features of Patients 
In our study, there were 30 patients harboring hemorrhagic adenomas (6 men, 24 women; age range 
17  to  62  years,  mean  age  40.50  ±   13.00  years)  and  30  patients  with  non-hemorrhagic  adenomas  
(8 men, 22 women; age range 22 to 55 years, mean age 37.50 ±  9.94 years). The numbers of clinical 
and subclinical pituitary apoplexy patients were 8 and 22, respectively. The eight patients with clinical 
pituitary apoplexy had several common clinical symptoms, including headache (8/8), nausea (7/8), 
vomiting  (7/8),  visual  field  defect  (7/8),  decreased  visual  acuity  (6/8),  ophthalmoplegia  (4/8),  
febrile (3/8), and altered consciousness (1/8). For the patients (n = 30) with hemorrhagic pituitary 
adenomas, histopathological assessment revealed that 18 patients had prolactinomas, five patients had 
non-functional adenomas, three had multihormonal adenomas, two had gonadotropinomas and two had 
GH-secreting adenomas. In the patients (n = 30) with non-hemorrhagic pituitary adenomas, 21 patients 
had prolactinomas, five patients had non-functioning adenomas, two had gonadotropinomas, and two 
had GH-secreting adenomas. Invasive tumors were found in four patients (hemorrhagic tumor in one 
patient and non-hemorrhagic tumors in three). Intratumoral hemorrhage was not observed to correlate 
with tumor size, hormone types, angiogenesis and tumor invasion (data not shown).  
2.2. Increased Expression of TNF-α, VEGF and MMP-9 in Hemorrhagic Pituitary Adenoma Tissues 
To determine whether TNF-α is associated with intratumoral hemorrhage in pituitary adenomas,  
we  examined  TNF-α  expression  in  hemorrhagic  and  non-hemorrhagic  pituitary  adenomas. 
Immunofluorescence  demonstrated  prominent  positive  cytoplasmic  specific  staining  of  TNF-α  in 
pituitary  adenomas  (Figure  1A).  Western  blotting  showed  increased  protein  levels  of  TNF-α  in 
hemorrhagic  pituitary  adenomas  compared  with  non-hemorrhagic  tumors  (P  <  0.05).  To  further 
elucidate the potential mechanisms by which TNF-α induces hemorrhage in pituitary adenomas, the 
expression levels of VEGF and MMP-9 were determined. Western blotting showed that the protein 
levels of TNF-α, VEGF and MMP-9 in hemorrhagic pituitary adenomas were significantly higher than 
those in non-hemorrhagic specimens (P < 0.05) (Figure 1B). The mRNA levels of VEGF and MMP-9 
were significantly higher in hemorrhagic pituitary adenomas (P < 0.05) (Figure 1C).  
2.3. Correlation of TNF-α and Hemorrhage-Associated Genes Expression in Hemorrhagic and  
Non-Hemorrhagic Pituitary Adenoma Tissues 
As statistically significant higher expression levels of TNF-α protein were found in hemorrhagic 
pituitary  adenomas,  correlations  between  TNF-α  and  hemorrhage-associated  genes  (VEGF  and  
MMP-9) expression in pituitary adenoma tissues were analyzed. The Pearson correlation coefficients 
for VEGF and MMP-9 versus TNF-α protein expression in pituitary adenomas were 0.674 (P = 0.01) 
and 0.521 (P = 0.01), respectively. Int. J. Mol. Sci. 2011, 12                       
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Figure  1.  Increased expression levels of tumor necrosis factor alpha (TNF-α), vascular 
endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in hemorrhagic 
pituitary  adenomas.  (A)  Representative  immunofluorescence  staining  of  TNF-α.  
Scale  bar  =  5  μm;  (B)  Western  blot  results  showed  higher  expression  levels  of  
TNF-α,  VEGF  and  MMP-9  in  hemorrhagic  pituitary  adenomas  (P  <  0.05);  
(C) Densitometric analysis normalized with GAPDH as loading control was also shown; 
(D) Real-time RT-PCR was performed with the same tissues and showed increased mRNA 
expression levels of TNF-α, VEGF and MMP-9 (P < 0.05). All of the bars in the figures 
show mean ±  SD. * P < 0.05. 
(A)  (B) 
   
(C)  (D) 
   
2.4. Hemorrhagic Incite Has no Effect on MMP-9 and VEGF Expression 
Although hemorrhagic pituitary adenomas display higher levels of VEGF and MMP-9 than those in 
non-hemorrhagic tumors, this phenomenon may be an effect rather than a cause of hemorrhagic incite. 
To clarify this question, we injected whole blood (500 µ L) or 0.9% saline into subcutaneous MMQ 
pituitary tumor cell xenografts and then analyzed the effect of blood injection on protein expression of 
VEGF and MMP-9 in these tumors. The results indicated that blood has no significant enhancing 
effect on protein expression of VEGF and MMP-9 in MMQ cell xenografts (Figure 2). 
2.5. TNF-α Inhibits Proliferation and Increases Hemorrhage-Associated Genes Expression of MMQ 
Cells in Vitro 
To define the role of TNF-α in stimulating hemorrhage-associated genes expression, the effect of 
TNF-α on cell proliferation and hemorrhage-associated genes (VEGF and MMP-9) expression was 
examined  in  the  MMQ  pituitary  adenoma  cell  line.  MMQ  cells  were  treated  with  different 
concentrations  of  TNF-α  (0,  10,  20  ng/mL)  for  24  h.  A  dose-dependent  inhibitory  effect  on  cell Int. J. Mol. Sci. 2011, 12                       
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proliferation was observed. After a 24 h incubation period, TNF-α stimulation at concentrations of  
10 and 20 ng/mL inhibited basal cell growth by 9 ±  3.4% (P < 0.05) and 16 ±  4.2% (P < 0.05), 
respectively.  Based  on  this  result,  we  used  TNF-α  at  concentration  of  20  ng/mL  for  following 
stimulation.  After  24  h  of  TNF-α  (20  ng/mL)  exposure,  MMQ  cells  showed  significantly  higher 
protein and mRNA levels of VEGF and MMP-9 expression (P < 0.05), as determined by western blot 
analysis (Figure 3A,B) and real-time RT-PCR (Figure 3C). To determine whether VFGF regulate 
MMP-9 bioavailability in MMQ cells, the effect of VEGF inhibitor bevacizumab on TNF-α mediated 
VEGF  and  MMP-9  expression  were  investigated.  Bevacizumab  significantly  inhibited  TNF-α 
mediated  VEGF  up-regulation,  while  blocking  of  VEGF  did  not  affect  TNF-α  mediated  MMP-9  
up-regulation.  This  trend  was  also  confirmed  in  zymography  (Figure  3D),  the  zymographic 
densitometry value for the TNF-α group was 1.15 ±  0.12, and 1.21 ±  0.19 for the bevacizumab plus 
TNF-α group (P > 0.05). 
Figure 2. Effect of blood injection on protein expression levels of VEGF and MMP-9 in 
xenograft tumors. Whole blood (500 µ L) or 0.9% saline was injected into subcutaneous 
xenograft tumors (3  tumors per condition),  after  two days,  tumors  were  harvested and 
protein was extracted for western blot. (A) Representative western blots of xenografts from 
the blood injection group and the control group. No significant enhancing effect of blood 
injection on protein expression of VEGF and MMP-9 was observed; (B) Densitometric 
analysis  normalized  with  GAPDH  as  loading  control  was  also  presented.  Data  are 
expressed as mean ±  SEM. NS: not significant. 
(A)  (B) 
   
2.6. TNF-α Causes Hemorrhagic Transformation and Increases Hemorrhage-Associated Genes 
Expression in MMQ Cell Xenografts in Mice 
To translate our above in vitro findings into an in vivo model of TNF-α-dependent hemorrhagic 
transformation, next we evaluated the effect of rhTNF-α on MMQ cell tumor xenograft growth in 
athymic nude mice. HE staining showed that rhTNF-α administration of one week caused marked 
hemorrhage in xenograft tumors (5 out of 6) in comparison to vehicle control (0 out of 6) (Figure 4A). 
We  next  investigated  the  possible  mechanisms  underlying  rhTNF-α  mediated  hemorrhagic  
transformation in vivo. Western blot analysis clearly showed increased protein levels of MMP-9 and 
VEGF  in  the  xenograft  tumors  treated  with  rhTNF-α  compared  with  the  control  (Figure  4B).  As  
MMP-9 appeared not to be affected by VEGF in the in vitro study, we tested whether suppression of 
VEGF  or  MMP-9,  either  alone  or  in  combination,  could  reduce  TNF-α  mediated  hemorrhagic Int. J. Mol. Sci. 2011, 12                       
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transformation in nude mice. Using a VEGF inhibitor (bevacizumab) and a broad MMP inhibitor 
(GM6001), we administered either or both of them to different groups of mice one week before and 
during TNF-α treatment, and then the rate of TNF-α induced hemorrhage in each group was examined 
using  HE  staining.  One  out  of  five  mice  in  the  VEGF  plus  MMP-9  inhibitors  group  displayed 
hemorrhagic  xenograft  tumors,  while  two  in  the  VEGF  inhibitor  group  and  three  in  the  MMP-9 
inhibitor group were found (Figure 4A). The results indicate that VEGF or MMP-9 inhibitors, either 
alone or in combination, could attenuate TNF-α mediated hemorrhagic transformation in MMQ cell 
xenograft tumors. Together, these results clearly show that TNF-α may contribute to the development 
of hemorrhage in MMQ tumor xenografts via upregulation of VEGF and MMP-9. 
Figure  3.  Effect  of  TNF-α  on  VEGF  and  MMP-9  expression  in  lactotroph  MMQ  rat 
pituitary  tumor  cells.  Cells  were  treated  with  TNF-α  (20  ng/mL)  or  pretreated  with 
bevacizumab (5 mg/mL) for 72 h and an additional 24 h with TNF-α (20 ng/mL), and then 
VEGF  and  MMP-9  expression  were  determined  via  western  blot  analysis  (A,  B)  and  
real-time RT-PCR (C). The supernatant of cells was also subjected to zymography (D). 
TNF-α  induced  higher  protein  and  mRNA  levels  of  VEGF  and  MMP-9  expression. 
Bevacizumab attenuated TNF-α mediated VEGF expression but had no effect on TNF-α 
mediated MMP-9 expression. Ratios of density were individually normalized with GAPDH. 
The bars show mean ±  SEM (n = 3). *, P < 0.05. NS: not significant. 
(A)  (B) 
   
(C)  (D) 
 
 
2.7. Discussion 
The  mechanism  underlying  hemorrhagic  transformation  in  pituitary  adenomas  remains  unclear.  
In  the  present  study,  we  provide  the  first  evidence  that  TNF-α  plays  a  key  role  in  hemorrhagic Int. J. Mol. Sci. 2011, 12                       
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transformation  in  pituitary  adenomas.  Our  results  reveal  an  association  of  TNF-α  elevation  with  
up-regulation of VEGF and MMP-9 in hemorrhagic pituitary adenomas and demonstrate that TNF-α 
promotes hemorrhagic transformation in MMQ pituitary adenoma cell xenografts via up-regulation of 
VEGF and MMP-9.  
Figure 4. Mouse tumor hemorrhage, pathology and the expression levels of VEGF and 
MMP-9. Mice were implanted with MMQ cells. After two weeks, mice were treated with 
saline,  rhTNF-α,  rhTNF-α  plus  bevacizumab,  rhTNF-α  plus  GM6001,  rhTNF-α  plus 
bevacizumab  and  GM6001.  Five  mice  in  each  group.  rhTNF-α  (10,000  U/kg  i.m.), 
bevacizumab (10 mg/kg i.p.) and GM6001 (10 mg/kg i.p.) were implemented twice per 
week. Both bevacizumab and GM6001 were administrated one week before and during 
TNF-α treatment. Tumors were harvested after one week rhTNF-α treatment. (A) Tumors 
of  each  group  and  representative  pictures  of  hemorrhagic  tumor  and  HE  staining.  
Scale bar = 5 μm; (B) Protein expression levels of VEGF and MMP-9 in tumors after 
treatment.  Western  blot  analysis  revealed  the  increased  VEGF  expression  in  tumors  of 
rhTNF-α and rhTNF-α/GM6001 treated mice and increased MMP-9 expression in those of 
rhTNF-α  and  rhTNF-α/bevacizumab  treated  mice.  Bevacizumab  inhibited  VEGF 
expression with reduced appearance of VEGF band. GM6001 inhibited MMP-9 expression 
with  reduced  appearance  of  MMP-9  band.  (C)  Densitometric  analysis  of  western  blot 
results.  GAPDH  was  an  internal  control  to  normalize  gel  loading.  *  P  <  0.05.  
NS: not significant. 
(A) 
 
(B)  (C) 
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TNF-α  is  a  critical inflammatory  cytokine  that plays  a  central  role  in initiating  and promoting 
inflammatory responses [4,6]. Previous studies have demonstrated that TNF-α participates in many 
hemorrhagic pathologic processes. TNF-α promoter polymorphisms have been found to be associated 
with hemorrhage in brain arteriovenous malformation, spontaneous deep intracerebral hemorrhage, 
and hemorrhage in trauma [5,9,28]. Recently TNF-α has been reported to be involved in aneurysm 
formation, growth and rupture [4]. In addition to aforementioned, TNF-α is present in both normal and 
tumor pituitary cells, indicating a possible role for TNF-α in the development of pituitary adenomas. In 
this study, elevated TNF-α level was associated with hemorrhagic pituitary adenomas, and TNF-α 
administration  promoted  hemorrhagic  transformation  in  MMQ  pituitary  adenoma  cell  xenografts. 
These findings indicate an important role of TNF-α in hemorrhagic transformation of pituitary adenomas. 
Considering that TNF-α may be involved in hemorrhagic transformation of pituitary adenomas,  
we next explored the possible mechanisms underlying its role in hemorrhagic transformation. TNF-α 
has  been  shown  to  stimulate  VEGF  expression  [10].  VEGF  induces  not  only  angiogenesis  and  
vascular hyperpermeability, but also microvessel vasodilation [12]. All these changes may predispose  
vessels  to  rupture,  leading  to  various  hemorrhagic  events.  In  addition  to  experimental  evidence 
aforementioned  [13–15],  elevated  VEGF  levels  have  been  demonstrated  in  hemorrhagic  pleural 
effusion of lung cancer [29], vitreous hemorrhage [30], cerebral hemorrhagic infarction and hemorrhage 
of  retinal  angiomas  [31,32].  In  terms  of  pituitary  adenoma,  studies  dealing  with  the  association 
between VEGF expression and pituitary adenoma hemorrhage have been controversial [16–19]. The 
discrepancy may be due to the differences in patient selection, sample sizes and hormone-secreting 
types of tumors studied. Another explanation is that the development of intratumoral hemorrhage may 
require different threshold levels of VEGF in different patients, because the absolute levels of VEGF 
are critical to its function in both physiological and pathological conditions [13]. This explanation is 
exemplified in part by the 4-fold elevation of VEGF secretion required for an acute development of 
hemorrhage in glioma cell xenografts [13].  
In addition to VEGF, MMP-9 is also known to be regulated by TNF-α and has been implicated in 
hemorrhagic  transformation  [11].  MMP-9  has  broad  substrate  specificity  and  degrades  several 
extracellular matrix components. MMP-9 activation may lead to destruction of microvascular integrity 
and vascular remodeling, which results in hemorrhagic events [20,21]. Hemorrhagic pituitary adenomas 
express higher levels of MMP-9 [24], suggesting a possible role for MMP-9 in the development of 
hemorrhage within pituitary adenomas. In this study, the TNF-α mediated up-regulation of VEGF and 
MMP-9 was confirmed in MMQ cells. These data are consistent with previous findings of TNF-α in 
other  human  cells  [6,10,33].  Moreover,  the  inefficiency  of  VEGF  inhibitor  in  preventing  TNF-α 
mediated MMP-9 expression exclude the possible direct effects of VEGF on MMP-9 expression in 
MMQ cells. 
In  this  study,  elevated  VEGF  and  MMP-9  expression  in  hemorrhagic  pituitary  adenomas  was 
demonstrated. Furthermore, TNF-α administration induced VEGF and MMP-9 expression and caused 
hemorrhagic transformation in MMQ cell xenografts. These findings confirm the pivotal role of TNF-α 
in mediating VEGF and MMP-9 up-regulation in hemorrhagic transformation of pituitary adenomas. 
Contrary to our expectations, the application of both VEGF and MMP-9 inhibitors attenuated but not 
abrogated TNF-α mediated hemorrhagic transformation. These results suggest that, besides VEGF and 
MMP-9, other targets may also contribute to hemorrhagic transformation. Our in vivo results may raise Int. J. Mol. Sci. 2011, 12                       
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a question as whether the remaining hemorrhagic transformation in tumors treated with inhibitors is 
caused by the inhibitor drug itself. However, in this study, inhibitor treatment for one week before  
the  TNF-α  administration  had  not  caused  obvious  intratumoral  hemorrhage  in  xenograft  tumors  
during the week. This observation excluded the possibility of side effect of the inhibitory drugs on 
hemorrhage transformation.  
There is an inherent limitation of our experimental results from patient samples, because whether 
they  are  a  cause  or  an  effect  of  hemorrhagic  incites  remains  unclear.  However,  the  effects  of 
hemorrhage have been reported to generally abate over the first week in animal studies [34,35]. As our 
institution is a tertiary care medical center, there was a considerable delay between the symptom onset 
and referral to our clinic in our patients. The median duration of symptom prior to surgery was two 
weeks in our patients. In addition, we also investigated samples from subclinical pituitary adenoma 
patients who might have even longer duration of hemorrhage prior to surgery [36]. We found there was 
no significant difference between clinical and subclinical hemorrhagic pituitary adenoma tissues in the 
western blot results. These two kinds of hemorrhagic tissues both displayed higher protein levels of 
TNF-α, VEGF and MMP-9 than non-hemorrhagic tumors. Furthermore, we also determined the effect 
of  blood  injection  on  MMP-9  and  VEGF  protein  expression  in  xenograft  tumors  and  found  no 
significant difference between tumors of blood group and those from control group. This result also 
suggests  that  elevated  MMP-9  and  VEGF  protein  levels  may  be  a  cause  rather than  an  effect  of 
hemorrhagic incite in pituitary adenomas. 
Apoplectic pituitary adenomas display three different pathologic types: hemorrhage, hemorrhagic 
infarction and infarction, and these three pathologic types are present in nearly equal numbers [3]. 
Moreover, about 30% of patients presenting with pituitary tumor apoplexy have precipitating factors or 
associated  events  [2].  Thus,  it  seems  likely  that  multiple  mechanisms  may  be  involved  in  the 
pathogenesis of pituitary adenoma apoplexy. This study confirmed that TNF-α promoted hemorrhagic 
transformation  via  up-regulation  of  VEGF  and  MMP-9  in  a  mice  model  of  pituitary  tumor  cell 
xenografts. The data support the view that TNF-α mediated up-regulation of VEGF and MMP-9 is a 
contributory  cause for hemorrhagic transformation  in pituitary adenomas. Although TNF-α  cannot 
explain all the pathology seen in pituitary adenoma hemorrhage, it is clearly an important component 
to  the  pathology.  TNF-α  may  act alone  or  perhaps  in  concert  with environmental  exposures,  risk 
factors  or  other  diseases  to  promote  the  development  of  pituitary  adenoma  hemorrhage.  Besides  
TNF-α,  there  may  be  many  other  mechanisms  underlying  pituitary  adenoma  hemorrhage,  which 
warrants further studies. 
3. Materials and Methods 
3.1. Patients and Samples 
The study was approved by the Research Ethics Committee of the Huazhong University of Science 
and Technology, Wuhan, China. Prior informed consent was obtained from all patients enrolled in this 
study. All specimens were made anonymous according to ethical standards. 
From May 2009 to December 2010, a series of 60 surgically removed pituitary adenomas were 
obtained from patients undergoing transsphenoidal surgery at the Department of Neurosurgery, Tongji Int. J. Mol. Sci. 2011, 12                       
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Hospital, Huazhong University of Science and Technology, Wuhan, China. Each sample was bisected. 
One half was immediately frozen at −80 ° C until protein and RNA extraction. The other half was fixed 
with 10% formalin and embedded in paraffin for histology and immunofluorescence. 
3.2. Histology and Immunofluorescence 
The sections were deparaffinized and rehydrated in successive xylene and alcohol, and then stained 
with  Hematoxylin  and  Eosin  for  the  morphological  diagnosis.  For  immunofluorescence,  paraffin 
sections  of  tumors  were  deparaffinized  and  rehydrated  by  successive  washes  with  xylene,  graded 
ethanol. Antigen retrieval was accomplished in microwave oven in 100 mM sodium citrate buffer  
(pH  6.0)  for  10 min and then cooled to  room temperature  for 20  min. Subsequently, slides were 
incubated with 10% normal serum followed by the primary anti-TNF-α antibody (Millipore, 1:500) 
and  incubated  overnight  at  4  ° C.  The  slides  were  then  incubated  with  corresponding  Alexa  
fluor-labeled secondary antibody (Invitrogen) for 30 min. For quantification, 3 to 5 “hotspot” areas 
were captured for each slide by two individuals. Digital images were analyzed and quantified using 
Image-Pro Plus. 
3.3. Cell Culture 
MMQ, a rat prolactin-secreting pituitary tumor cell line, was purchased from ATCC (American 
Type Culture Collection, Manassas, VA) and routinely cultured in F-12 medium supplemented with 
2.5% fetal bovine serum and 15% equine serum at 37 ° C in a humidified air atmosphere containing 5% 
carbon dioxide in T-75 flasks. MMQ cells were stimulated with 20 ng/mL TNF-α (Abcam) or saline 
for 24 h, and then were analyzed for possible effects of TNF-α on VEGF and MMP-9 expression. In 
order to evaluate the impact of VEGF blockade on TNF-α mediated MMP-9 expression in MMQ cells, 
another group of cells were pretreated with VEGF inhibitor bevacizumab (Roche) (5 mg/mL) for 72 h 
and then TNF-α (20 ng/mL) was added for an additional 24 h. After incubation, cells were harvested 
for western blot and real-time RT-PCR analysis. 
3.4. Cell Viability Assay 
The effect of TNF-α  on cell  viability was carried  out  using Cell  Counting  Kit-8 (Boster  Co.). 
Briefly, MMQ cells were plated in 96-well plates (20,000/well). The cells were treated with TNF-α at 
concentrations of 0, 10, 20 ng/mL. After 24 h incubation, 10 μL of the CCK-8 solution was then added 
to each well of the plate, and then the plate was incubated for another 1 h. The absorbance was 
measured at 450 nm using a 96-well plate reader. 
3.5. Western Blot Analysis 
Expression of VEGF and MMP-9 protein from adenoma tissues, cells and xenograft tumors were 
determined by western blot analysis. Tumors or cells were thawed on ice and homogenized at 4 ° C in 
lysis buffer for extracting total protein. The protein was quantitated using a bicinchoninic acid (BCA) 
reagent. Equivalent amounts of protein (30 μg) from each sample were separated, under denaturing 
conditions,  by  electrophoresis  on  10%  SDS-PAGE  gels  (polyacrylamide  gels  containing  sodium Int. J. Mol. Sci. 2011, 12                       
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dodecyl sulfate). The protein bands were transferred by electroblotting to nitrocellulose membranes. 
The  blots  were  incubated  1  hour  with  PBS  contain  0.1%  Tween  20  (PBST)  and  5%  powdered  
milk,  and  then  incubated  overnight  with  anti-human/rat  MMP-9  antibody  (Santa  Cruz,  1:1000),  
anti-human/rat  VEGF  antibody  (Santa  Cruz,  1:1000)  and  anti-human/rat  GAPDH  antibody  (Cell 
Signaling,  1:3000).  The  membranes  were  washed  six  times  with  TBST  (10  mM  Tris· HCl,  
pH 8.0/150 mM NaCl/0.1% Tween 20), and then were incubated with relative second antibodies and 
washed six times with TBST. Bands were visualized by ECL (Thermo-Pierce). In each tumor sample, 
protein levels were normalized to that of GAPDH as a loading control. 
3.6. Zymography 
MMQ  cells  (1  ×   10
6)  were  cultured  with  TNF-α  (20  ng/mL)  or  TNF-α  plus  VEGF  inhibitor 
bevacizumab  (5  mg/mL)  in  serum  free  DMEM  medium,  after  24  h  incubation,  the  supernatant  
was collected, and centrifuged at 2000 rpm for 10 min. Protein concentration was determined and 
electrophoresed on 7.5% non-reducing SDS–PAGE gels containing 2 mg/mL gelatin as a substrate at 
constant voltage. After electrophoresis, the gels were rinsed in renaturation buffer (2.5% Triton X-100) 
on a shaker for 30 min to remove SDS and were incubated overnight at 37 ° C in a water bath in 
activation buffer composed of 50 mmol/L Tris-HCl (pH 7.5), 5 mmol/L CaCl2. Gels were stained 
using  0.5%  Coomassie  blue  R-250  (Bio-Rad)  for  2  h,  followed  by  appropriate  destaining.  MMP 
activity was detected as a band on a dark blue background and quantified densitometrically using 
Image-Pro Plus. 
3.7. Real-Time RT-PCR 
Total  RNA  was  isolated  from  cell  culture  and  frozen  tumor  tissues  using  RNeasy  Mini  kit 
(QIAGEN) according to the manufacturer’s instructions. Real-time RT-PCR was done using TaqMan 
one-step  RT-PCR  master  mix  kit and  gene  specific taqman  gene  expression  assay  kits  in  a  7300  
real-time PCR system (Applied Biosystems). PCR amplification was carried out in a 20 µ L reaction 
volume containing 200 ng of cDNA, 1.8 µ M each of forward and reverse primers, and 10 µ L Fast 
SYBR Green Master Mix (Applied Biosystems). The PCR reactions were initiated with denaturation at 
95 ° C for 10 min; followed by 40 amplification cycles at 95 ° C for 15 s and 60 ° C for 1 min. Samples 
were run in triplicate and results were averaged. CT was calculated by analysis software SDS 2.2.1 
(Applied  Biosystems).  Analysis  of  gene  expression  changes  were  calculated  using  the  2-ΔΔCT 
method. The normalized expression ratio (fold induction) was calculated by 2-ΔΔCT = fold induction. 
Statistical analyses were performed using the CT ±  SD values. The primer sequences used for real-time 
RT-PCR for Human TNF-α F: TGGAGAAGGGTGACCGACTC, R: TGCCCAGACTCGGCAAAG; 
Human  MMP-9  F:  CCCTGGAGACCTGAGAACCA,  R:  CCCGAGTGTAACCATAGCGG;  
Human  VEGF  F:  TGTGAATGCAGACCAAAGAAAG,  R:  GCTTTCTCCGCTCTGAGCAA;  
Human  GAPDH  F:  GAAGGTGAAGGTCGGAGTC  R:  GAAGATGGTGATGGGATTTC;  
Rat  VEGF  F:  TGTGCGGGCTGCTGCAATGAT,  R:  TGTGCTGGCTTTGGTGAGGTTTGA;  
Rat  MMP-9  F:  CTTTGTAGGGTCGGTTCTG,  R:  GAGTGGATAGCTCGGTGG;  Rat  GAPDH  F: 
GTCTTCACTACCATGGAGAAGG,  R:TCATGGATGACCTTGGCCAG;  Real-time  PCR  results 
were carried out by three replicate measurements of each sample. Int. J. Mol. Sci. 2011, 12                       
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3.8. Animal Xenografts 
Six week-old athymic nude mice were inoculated subcutaneously in the lower rear flank with MMQ 
cells suspended in 0.1 mL of PBS (1 ×  10
6 cells per mouse inoculation). rhTNF-α, bevacizumab and 
GM6001 were purchased from Weike Shanghai Biopharmaceutical Limited, Roche and Chemicon, 
respectively. Mice were randomized into five groups: control (saline) group, rhTNF-α group, rhTNF-α 
plus bevacizumab (a VEGF inhibitor) group, rhTNF-α plus GM6001 (a broad MMP inhibitor) group, 
rhTNF-α plus bevacizumab and GM6001 group, with five mice in each group. Treatments were started 
two weeks after cell injection. rhTNF-α (10,000 U/kg i.m.), bevacizumab (10 mg/kg i.p.) and GM6001 
(10 mg/kg i.p.) were implemented twice per week. Both bevacizumab and GM6001 were administrated 
one week before and during rhTNF-α treatment. Tumors were harvested after one week of rhTNF-α 
treatment. Half of each tumor was frozen in liquid nitrogen for protein analysis and the other half was 
fixed in 10% formalin for histology analysis. 
3.9. Blood Infusion in Xenograft Tumors 
To  investigate  whether  hemorrhagic  incite  affects  MMP-9  and  VEGF  expression  in  pituitary 
adenoma  tissues, we injected whole blood (500 µ L) or  0.9% saline into subcutaneous  MMQ cell 
xenografts, respectively. Two days after injection, the mice were sacrificed and tumors were collected. 
Tumors from whole blood group (3 cases) and saline group (3 cases) were immediately frozen and 
then western blot analysis was performed for protein expression of MMP-9 and VEGF. 
3.10. Statistical Analysis 
Statistical  analyses  were  processed  and  analyzed  with  the  aid  of  SPSS  17.0  software.  For 
experiment with patient samples, results are expressed as the mean ±  SD. For in vitro and in vivo 
studies, values were expressed as mean ±  SEM. Student t-tests were used to compare hemorrhagic 
adenomas versus non-hemorrhagic tumors on protein and mRNA levels. Pearson correlation test was 
used to determine the correlations between VEGF, MMP-9 and TNF-α protein expression in tissues. 
Results from animal and cell culture studies were analyzed using Student t-tests. Probability values of 
less than 0.05 were considered statistically significant. 
4. Conclusions 
Taken together, our results show that TNF-α significantly correlates with intratumoral hemorrhage 
in  pituitary adenomas  and  induces  pituitary  adenoma hemorrhage  through  up-regulation  of VEGF  
and MMP-9. Based on these findings, our study demonstrates that TNF-α may play a role in the 
development of hemorrhage within pituitary adenomas. 
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